Prostate Cancer International is
for 2011 by Great NonProfits
Today’s news reports address items on: The burden of prostate cancer in Canada Pelvic lymph node dissection and RALP Data from early trials of sipuleucel-T in advanced prostate cancer Implementation of osteoporosis screening guidelines in prostate cancer patients
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Canada, guidelines, incidence, mortality, osteoporesis, pelvic lymph node dissection, PLND, Provenge, screening, sipuleucel-T | 3 Comments »
OK … so here are the results we have all been waiting for for the past few weeks — the data from the IMPACT trial comparing the survival of patients treated with three doses of sipuleucel-T (Provenge) to placebo in men with androgen-independent prostate cancer.
Filed under: Drugs in development | Tagged: androgen-independent prostate cancer, Dendreon, Provenge, sipuleucel-T | 2 Comments »
Dendreon has previously announced that the results of the IMPACT trial will be presented at the annual meeting of the American Urological Association at approximately 2:20 pm on Tuesday, April 28. The company has now announced that, in addition, it will hold a webcast conference call at 4:30 pm CT (5:30 pm ET, 2:30 pm [...]
Filed under: Drugs in development | Tagged: Dendreon, Provenge, sipleucel-T | Comments Off
Dendreon researchers have presented data from the PROTECT (PROvenge Treatment and Early Cancer Treatment) or P-11 Phase 3 trial suggesting that sipuleucel-T (Provenge) induces durable responses that can be maintained following an immune boost. These early data from the PROTECT trial were presented Sunday at the annual meeting of the American Association for Cancer Research [...]
Filed under: Drugs in development, Management, Treatment | Tagged: androgen-dependent, Provenge, sipleucel-T | Leave a Comment »
OK folks … please don’t shoot the messenger … I do not agree with the suggestions about the need for another trial in an article published today by the Financial Times. However, I would be a pretty poor reporter if I didn’t let you know this article is out there in a major international newspaper! [...]
Filed under: Drugs in development | Tagged: Dendreon, Provenge | 3 Comments »
According to a media release from Dendreon earlier this evening, there will be a conference call at 9 am EST/6 am PT tomorrow morning (Tuesday, April 14) at which the company will “review the outcome of the FINAL analysis of its IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial of PROVENGE® [...]
Filed under: Drugs in development | Tagged: Provenge, sipuleucel-T | Comments Off
For those who have come to the world of prostate cancer in the past 2 years or so, we recommend that, before you attempt to understand whatever happens on the day that Dendreon announces the results of the Phase III (IMPACT) trial of sipleucel-T, a.k.a. Provenge (expected some time this month), you read the well-constructed [...]
Filed under: Drugs in development | Tagged: Dendreon, Provenge | 2 Comments »
The “New” Prostate Cancer InfoLink has seen a couple of statements from members of the financial community in the last few days that could mislead the unwary into believing that Dendreon’s investigational immunotherapeutic agent, sipuleucel-T (Provenge), has already demonstrated a statistically significant survival benefit in its most recent Phase III clinical trial (the IMPACT trial)
Filed under: Drugs in development | Tagged: Dendreon, Provenge, sipuleucel-T | 1 Comment »
Today’s reports cover such topics as: Diets high in fish and seafood and prostate cancer risk Testosterone therapy and prostate cancer risk A new, first-in-class drug enters prostate cancer trials The science behind products like Provenge
Filed under: Diagnosis, Management, Prevention, Treatment | Tagged: diet, elesclomol, fish, Provenge, risk, seafood, sipleucel-T, testosterone | Leave a Comment »
Dendreon has just announced some data from an interim analysis of a Phase III, randomized, double-blind, placebo-controlled clinical trial (the so-called IMPACT or D9902B trial) designed to assess the safety and efficacy of the investigational agent Provenge (sipuleucel-T) compared to placebo in men with metastatic, androgen-independent prostate cancer.
Filed under: Drugs in development, Management, Treatment | Tagged: immunotherapy, Provenge | 4 Comments »
Dendreon has announced initiation of another Phase II trial of Provenge® (sipuleucel-T) for the treatment of advanced prostate cancer. According to the company, this multicenter trial, called ProACT (PROstate Active Cellular Therapy), has begun enrolling 120 patients with metastatic, androgen-independent prostate cancer.
Filed under: Drugs in development, Management, Treatment | Tagged: cancer, immunotherapy, prostate, Provenge, vaccine | Leave a Comment »
In additional news breaking today: Dendreon Corp. is predicting interim results of the IMPACT study of Provenge in metastatic, androgen-independent prostate cancer by October 2008 The FDA has refused to approve an experimental, topical treatment for erectile dysfunction
Filed under: Drugs in development, Management, Treatment | Tagged: cancer vaccine, Dendreon, ED, erectile dysfunction, hormone, NexMed, prostate, Provenge, refractory | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site